Cline Darren S 4
4 · Xenon Pharmaceuticals Inc. · Filed Jan 9, 2026
Insider Transaction Report
Form 4
Cline Darren S
Chief Commercial Officer
Transactions
- Award
Share Option (Right to Buy)
2026-01-09+40,000→ 40,000 totalExercise: $42.15Exp: 2036-01-08→ Common Shares (40,000 underlying) - Award
Restricted Share Units
2026-01-09+20,000→ 20,000 totalExercise: $0.00→ Common Shares (20,000 underlying)
Footnotes (2)
- [F1]Vesting 25% on January 9, 2027, and 75% vesting thereafter over the course of the next 3 years, in equal amounts, on the last day of each month.
- [F2]Each restricted share unit represents a contingent right to receive one Common Share vesting 25% on each of the first four anniversaries of the date of grant, beginning on January 9, 2027.